Arizona Is Going the Wrong Direction

The national headline — 13.2% fewer overdose deaths in the 12-month period ending January 2026 — has not reached Arizona.

A peer-reviewed study in Drug and Alcohol Dependence published in May 2026 documented what state epidemiologists and harm reduction workers on the ground had been watching for months: Arizona overdose deaths were up 20% in January through August 2025 compared to the same period in 2024. Deaths specifically involving fentanyl rose 40% in that window. January, February, March, and April of 2025 each set all-time monthly records for Arizona overdose deaths.

The demographics make this worse. The 18-to-24 age cohort saw a 35% increase. Hispanic Arizonans, 43%. Black Arizonans, 25%. These are not marginal variations on a trend — they are the sharpest increases, in the youngest and most underserved populations, in a state already running above the national mortality rate.

In Maricopa County, the numbers from 2024 already told a grim story: fentanyl was involved in 59% of fatal overdoses and methamphetamine in 67%, with the county averaging more than three fentanyl deaths per day. The 2025 trajectory suggests those numbers have continued climbing.

The state is not sitting still. AHCCCS received $34.8 million in year one of the federal SOR IV grant and is submitting for years two and three. Arizona’s portion of the One Arizona opioid settlement — potentially $1.215 billion over 18 years — is beginning to move into treatment infrastructure. The state has earmarked portions of those funds for prison/jail treatment, border interdiction (the Phoenix metro is a primary fentanyl transit point from Sinaloa), and grants to treatment facilities.

The timing problem is this: federal and settlement funds move on grant cycles. Overdose deaths do not. The organizations doing the fastest-response work — peer outreach, low-barrier buprenorphine clinics, naloxone distribution to active users — are the ones least connected to the slow-moving institutional funding streams.

Arizona’s counter-trend is both a data point and an argument. The data point is that statewide improvement is not guaranteed even in a year when national numbers are improving. The argument is that geographic and demographic specificity matters more than national averages — and that the communities with the fewest resources are, predictably, the ones where the epidemic is still accelerating.

---

Arizona-specific coverage of the opioid crisis, SOR grant funding, and AHCCCS policy changes is tracked in the Arizona Watch section.